



Company Announcement

Thursday 27th January 2011

Melbourne, Australia and Baar, Switzerland

Clinuvel hosts 3rd Annual Scientific & Clinical Excellence Meeting (ASCEM III)

Global experts' forum reviews updates on photoprotection, melanocyte signalling and melanocortins

Clinuvel Pharmaceuticals Limited (**ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY**) today announced that it had hosted its third Annual Scientific & Clinical Excellence Meeting (ASCEM III) in Switzerland on 23-24 January.

The nine ASCEM III invitees and delegates – global leaders and experts in photomedicine, dermatology and molecular biology - convened in Luzern during a two-day seminar to present and discuss the advances in their field of expertise.

Over the past three years, the ASCEM has become a forum where the year's scientific and clinical advances in UV damage, malignant transformation and photoprotective therapies are reviewed. These topics are most relevant to Clinuvel's ongoing development of SCENESSE® (afamelanotide) and CUV9900, novel melanocortin drugs.

Following the success of the meeting, Clinuvel intends to host a satellite symposium on "**Advances in the science of skin and UV, and the role of melanocortins**" during the 20th Congress of the European Association of Dermatology and Venereology (EADV) in Lisbon, Portugal. Over 10,000 dermatologists and other specialists attend the annual EADV Congress, one of the world's premier medical events, scheduled for October 20-24. The leading scientists and clinical experts worldwide will be invited to attend this symposium.

The ASCEM III focused on scientific and clinical advances, specifically:

- Melanocortin 1 receptor (MC1R) signalling and other signalling pathways;
- Melanogenesis and photoprotection;
- Pigmentation and pigmentary disorders;
- Ultraviolet radiation damage and its role on malignant transformation of skin; and
- Clinical use of alpha-MSH analogues, including Clinuvel's drug SCENESSE® (afamelanotide)

Clinuvel's Chief Scientific Officer, Dr Hank Agersborg, highlighted the significance of the interest in melanocortins in the medical and scientific community.

"What started as a select panel of global experts in their specialties has now grown to an annual forum where heads of research institutes and academia meet to exchange in a structured fashion the current thinking in the fields of relevant science and clinical care. Usually, scientists and clinicians do not meet at open forums, and Clinuvel's objective of bringing together the world's prominent experts for mutual gain of knowledge is being fulfilled. Clinuvel's focus on photoprotection and malignant transformation seems to be much appreciated.

"We are not surprised by the growing interest in areas such as UV mutagenicity, dermal response and melanocortins, as these topics are most relevant to the public questions on causality of skin cancers" Dr Agersborg said.

- End -

For more information go to <http://www.clinuvel.com>.

For more information contact:

Australia: Clinuvel Pharmaceuticals Limited, T: +61 3 9660 4900
Europe: Clinuvel AG, T: +41 41 767 45 45
E: investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, SCENESSE® (afamelanotide) for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

**Level 11 / 330 Collins Street
Melbourne, Victoria 3000
Australia**

**T +61 3 9660 4900
F +61 3 9660 4999**

www.clinuvel.com